Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical short communication

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series

Marcello Moccia a,⁎,1, Antonio Riccardo Buonomo b,⁎,1, Riccardo Scotto b, Giulio Viceconte b, Mariano Nobile b, Roberta Lanzillo b, Vincenzo Brescia Morra a, Ivan Gentile b, on the behalf of the Federico II COVID-19 Team

a Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Federico II University, Naples, Italy
b Department of Clinical Medicine and Surgery, Section of Infectious Diseases, Federico II University, Naples, Italy

ARTICLE INFO

Keywords:
Multiple sclerosis
COVID-19
Treatment
Monoclonal antibodies

ABSTRACT

We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).

1. Introduction

Multiple sclerosis (MS)-related disability and comorbidities can increase the risk of severe coronavirus disease-2019 (COVID-19) outcomes from severe acute respiratory syndrome–related coronavirus (SARS-CoV-2) infection [1]. Also, some disease-modifying treatments (DMTs), including anti-CD20 monoclonal antibodies and sphingosine-one-phosphate (SIP) modulators, can reduce the response to anti-SARS-CoV-2 vaccination (i.e., reduced seroconversion and/or cellular response) [2–4], and can subsequently be responsible for more severe COVID-19 outcomes, including hospitalizations and intensive care unit admissions [5–7].

There is a wide spectrum of COVID-19 clinical symptoms at presentation, that can be described using the Ordinal Scale for Clinical Improvement (OSCI), a 9-point scale, where 0 corresponds to no infection and 8 to death [8]. Patients with 0–2 OSCI Score have mild-to-moderate disease, characterized by at least one COVID-19 related symptom (e.g., cough, fever, sore throat, rhinorrhea) in the absence of oxygen therapy or need of hospitalization [8]. From March 2021, Italian regulatory bodies have approved a number of different monoclonal antibodies targeting the spike protein of SARS-CoV-2 (casirivimab-imdevimab 600 + 600 mg, bamlanivimab-etesevimab 1400 + 700 mg, sotrovimab 500 mg), to be administered as one-off intravenous infusion to patients with mild-to-moderate COVID-19 with risk factors of severe disease, including immunodepleting medications. Thus, monoclonal antibodies could be especially relevant to people with MS using DMTs. Indeed, monoclonal antibodies, if early administered, can significantly change the natural history of COVID-19 with faster recovery and lower rates of hospitalization and death [9].

Hereby, we reported on five people with MS, using immunodepleting DMTs (anti-CD20 monoclonal antibodies and SIP modulators), who had mild-to-moderate symptomatic COVID-19 (OSCI 0–2), and were treated with anti-SARS-CoV-2 monoclonal antibodies.

2. Cases

Demographic, MS and COVID-19 data are presented in Table 1.

2.1. Case 1

A 31-year-old woman on continuous treatment with fingolimod from 1.5 years, in the absence of clinical or MRI signs of disease activity, and with three doses of COVID-19 vaccination, presented with fever, cough, and fatigue on Dec 27, 2021, and, on the following day, tested positive to PCR SARS-CoV-2 nasal swab. On Jan 2, 2022, she received the infusion of bamlanivimab-etesevimab 1400 + 700 mg. Symptoms improved...
after 3 days and nasal swab was negative on Jan 7, 2022. No other medications nor hospital admissions were required. No relapses nor changes in disability were detected.

### 2.2. Case 2

A 48-year-old man, with past medical history of hepatitis C and Hashimoto’s thyroiditis, was on treatment with ocrelizumab for 2.5 years, in the absence of clinical or MRI signs of disease activity. He had two doses of COVID-19 vaccination, but no antibody response. On December 28, 2021, he presented with fever, cough and joint pains. On the same day, he tested positive for SARS-CoV-2 infection, which was later deemed to be Omicron (B.1.1.529) variant. On Jan 1, 2022, he received infusion of sotrovimab 500 mg. His symptoms improved after 3 days, and his nasal swab was negative after 12 days. No other medications nor hospital admissions were required. No relapses nor changes in disability were detected.

### 2.3. Case 3

A 44-year-old man was admitted to the Haematology Unit to receive inpatient chemotherapy for a rare cutaneous (panniculitis-like) T-cell lymphoma. He was on treatment with ocrelizumab from 2 years, in the absence of clinical or MRI signs of disease activity, and never vaccinated against COVID-19. Due to contact-tracing procedures, he tested positive to PCR SARS-CoV-2 nasal swab on Jan 13, 2022. On the following day, he presented with fever, headache, and joint pains. On Jan 17, 2022, he received the infusion of casirivimab-imdevimab 600 + 600 mg, followed by remdesivir infusions (200 mg on the first day and 100 mg on the next two days). His symptoms improved after 2 days. No other medications for COVID-19 were required; however, after 20 days, he still tested positive and required admission to COVID-19 ward to receive inpatient lymphoma treatment. He tested negative to COVID-19 on Feb 16, 2022. No relapses nor changes in disability were detected.

### 2.4. Case 4

A 53-year-old woman was on treatment with ocrelizumab from 3 years, in the absence of clinical or MRI signs of disease activity, and fully vaccinated against COVID-19 (booster dose on Jan 20, 2022), but without antibody response. On January 22, 2022, she presented with fever, cough, fatigue, joint pains, and gastrointestinal symptoms. On the following day, she tested positive to PCR SARS-CoV-2 nasal swab. On Jan 25, 2022, she received infusion of sotrovimab 500 mg. After 4 days, she had clear improvement of symptoms. Her nasal swab was negative after 16 days from symptoms’ onset. No other medications nor hospital admissions were required. No relapses nor changes in disability were detected.

### 2.5. Case 5

A 54-year-old woman was on treatment with fingolimod from 9 months due to clinical and MRI activity during previous treatment with interferon beta1a. She had her third dose of COVID-19 vaccination on Oct 5, 2021, in the absence of antibody response. On Feb 4, 2022, she presented with fever, cough, throat ache, fatigue, headache, and joint pains. On Feb 7, 2022, she tested positive to SARS-CoV-2 on nasal swab. On Feb 10, 2022, she received infusion of sotrovimab 500 mg monoclonal antibodies. After 2 days, she had clear improvement of symptoms, and, after further 2 days, tested negative to SARS-CoV-2 nasal swab. No other medications nor hospital admissions were required. No relapses nor changes in disability were detected.

### 3. Discussion

Our case series confirmed that MS patients using some DMTs mount low antibody titres after COVID-19 vaccination with subsequent risk of infection and worse outcomes [2,3], but highlighted the possibility to use safely monoclonal antibodies to treat COVID-19.

In particular, in our small case series, we referred to treatment with monoclonal antibodies MS patients with high risk of severe COVID-19

---

### Table 1

Demographics, MS clinical and treatment features, and COVID-19 timeline and treatment.

| #1 | #2 | #3 | #4 | #5 |
|----|----|----|----|----|
| Age | 31 | 48 | 44 | 53 | 54 |
| Sex | M | M | F | F | |
| Disease duration (years) | 3 | 4 | 22 | 16 | 15 |
| Subtype | RR | PP | RR | SP | RR |
| EDSS | 1.5 | 4.0 | 5.0 | 6.5 | 3.0 |
| DMT | Fingolimod (from Jun 12, 2020) | Ocrelizumab (5 infusions, most recent on Oct 1, 2021) | Ocrelizumab (3 infusions, most recent on Nov 12, 2021) | Ocrelizumab (6 infusions, most recent on Sep 17, 2021) | Fingolimod (from Feb 1, 2015) |
| Comorbidities | Hashimoto’s thyroiditis; previous hepatitis C | Panniculitis-like T cell lymphoma | None | None |
| Smoking | None | None | Past | Never | Current |
| COVID19 vaccination | Never | Past | Comirnaty (3rd dose on Nov 20, 2022) | Unvaccinated | Comirnaty (3rd dose on Jan 20, 2022) |
| Anti-SARS-CoV-2 (2019-nCoV) IgG after vaccination | Positive (IgG >2080 BAU/mL) | Negative | Comirnaty (2nd dose on Dec 10, 2021) | Negative | Negative |
| Pre-COVID19 lymphocytes | 950/ul | 1330/ul | 480/ul | 1400/ul | 420/ul |
| COVID19 onset | Dec 27, 2021 | Dec 28, 2021 | Jan 14, 2022 | Jan 22, 2022 | Feb 4, 2022 |
| COVID19 positive swab | Dec 28, 2021 | Dec 28, 2021 | Jan 13, 2022 | Jan 23, 2022 | Feb 7, 2022 |
| COVID19 symptoms | Fever, cough, fatigue, throat ache, headache, joint pains | Fever, cough, joint pains | Fever, headache, joint pains, gastrointestinal symptoms | Fever, cough, fatigue, headache, joint pains, gastrointestinal symptoms | Fever, cough, fatigue, throat ache, headache, joint pains |
| Monoclonal antibody treatment | Bamlanivimab-etesevimab (Jan 2, 2022) | Sotrovimab (Jan 1, 2022) | Casirivimab-imdevimab (Jan 17, 2022) | Sotrovimab (Jan 25, 2022) | Sotrovimab (Feb 10, 2022) |
| COVID19 negative swab | Jan 7, 2022 | Jan 12, 2022 | Feb 16, 2022 | Feb 7, 2022 | Feb 14, 2022 |
outcomes, as a consequence of low vaccination response (using ocrelizumab and fingolimod) or absence of vaccination [2,3], concomitant disease and treatment (e.g., chemotherapy for lymphoma), and high disability [1,5–7]. As such, while we included a pool of at-risk patients, we showed that, following the use of monoclonal antibodies for COVID-19, all of them fully recovered, in the absence of COVID-19 long-term symptoms, monoclonal antibodies’ side effects, or MS changes in terms of relapses or disability. Of note, no patient developed respiratory symptoms, nor required additional tests (e.g., chest imaging) and treatments (e.g., anti-inflammatory drugs), nor required hospitalization for COVID-19, thus suggesting that monoclonal antibodies achieved their expected effect, as in the general population [9], in the absence of safety concerns.

Our case series is limited by the small sample size, though comprehensive of MS patients at risk of worse COVID-19 outcomes due to a variety of reasons. In particular, looking at vaccine response, in line with previous studies [10], our case series confirmed the lack of serological response to vaccination in ocrelizumab-treated patients also after booster dose, while we did not assess T-cell responses [1,1–4]. In the current scenario of endemic COVID-19 and continuous treatment with immunosuppressive DMTs affecting both humoral and cellular immunity [15], passive immunization with monoclonal antibodies will likely be a cornerstone in preventing severe COVID-19 in this category of patients.

This is the first study describing safety and efficacy of monoclonal antibodies for COVID-19 in MS patients using immunosuppressant DMTs. Omicron variant was detected in Italy in Nov 2021, and became prevalent (>80%) in Jan 2022 [16,17]. Considering that casirivimab–imdevimab and bamlanivimab–etesevimab resulted poorly effective against Omicron BA.1 variant [9,18–23], from Jan 2022, we preferred sotrovimab. However, more recently, in vitro data showed that Omicron BA.2 variant may be poorly controlled by sotrovimab [17,18,21], and, thus, in the future, we shall consider the use of antivirals (such as remdesivir, molnupiravir, nirmatrelvir/ritonavir), also combined to monoclonal antibodies, as we already did in case 3. People with MS using DMTs and not mounting vaccination immunity may especially benefit from combination therapy with monoclonal antibodies and antivirals, which target two different SARS CoV-2 antigens (spike protein and polymerase, respectively), to overcome the risk of variant escape [17].

MS neurologists should be aware that MS patients more-at-risk of worse COVID-19 outcomes should be referred to treatment with monoclonal antibodies as early as possible. In the meanwhile, additional evidence should come from larger cohorts, also accounting for differences between DMTs and other MS (e.g., disability, disease duration) and clinical variables (e.g., age, comorbidities), in order to provide detailed guidance on the use of monoclonal antibodies in specific subcategories of MS patients.

Funding

The present study received no specific funding.

Disclosures

Marcello Moccia has received honoraria from Ipsen, Merck, Roche and Sanofi-Genzyme; and research grants from ECTRIMS-MAGNIMS, UK MS Society, and Merck. Roberta Lanzillo has received honoraria from Almirall, Biogen, Merck, Novartis, Roche and Sanofi-Genzyme. Vincenzo Brescia Morra has received honoraria from Almirall, Bayer, Biogen, Merck, Novartis, Roche and Sanofi-Genzyme; and research grants from Italian MS Foundation. Other authors have nothing to disclose.

Acknowledgements

We acknowledge the contribution of the Federico II COVID-19 Team: Amertrano Luigi, Amicone Maria, Beguinot Francesco, Castaldo Giuseppe, Cattaneo Letizia, Conte Maria Carmela Domenica, Cotugno Marisaroria, Di Filippo Giovanni, Di Filippo Isabella, Esposito Nunzia, Festa Lidia, Foggia Maria, Fusco Ludovica, Gallicchio Antonella, Gentile Ivan, Giaccone Agnese, Iervolino Anna, Iuliano Antonio, Lanzardo Amedeo, Licciardi Federica, Mercinelli Simona, Minervini Fulvio, Nobile Mariano, Pinchera Biagio, Portella Giuseppe, Reynaud Laura, Salemi Fabrizio, Sardanelli Alessia, Santo Marina, Schiano Morelli Nicola, Scordino Fabrizio, Scotto Riccardo, Stagnaro Francesca Maria, Tosone Grazia, troncone Daniele, Triassi Maria, Vecchietti Ilaria, Viceconte Giulio, Vozzella Emilia Anna, Zappulo Emanuela, Zotta Irene.

References

[1] M.P. Sormani, I. Schiavetti, L. Carmisciano, et al., COVID-19 severity in multiple sclerosis: putting data into context, Neurrol Neuroimmununol Neuroinflamm 9 (2022), e1105.
[2] E.C. Tallantyne, N. Vickaryous, V. Anderson, et al., COVID-19 vaccine response in people with multiple sclerosis, Ann Neurol 91 (2022) 89–100.
[3] M. Iannetta, D. Landi, G. Cola, et al., B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications, Front Immunol 12 (2022) 1–11.
[4] G. Bateh, H. Hegon, G. Traxler, et al., Comparing humoral immune response to SARS-CoV-2 vaccines in multiple sclerosis and healthy controls: an Austrian prospective multi-center cohort study, Eur J Neurol 29 (5) (2022) 1538–1544.
[5] S. Simpson-Yap, E. De Brouwer, T. Kalinick, et al., Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis, Neurology 97 (2021) e1870–e1885.
[6] A. Garzani, S. Patel, D. Bharkdha, et al., Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England, Mult Scler Relat Szed 57 (2022), 103458.
[7] D.R. Rose, A.Z. Mahadeen, A.K. Carbon, et al., Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis, Mult Sclerosis J Exp Transl Clin 7 (2021), 20552173211057110.
[8] World Health Organization, COVID-19 Therapeutic Trial Synopsis. https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis, 2020.
[9] M. Singh, E. de Wit, Antiviral agents for the treatment of COVID-19: progress and challenges, Cell Reports Med 3 (3) (2022), 100549.
[10] M. König, H.M. Torgauten, T.T. Tran, et al., Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination, JAMA Neurol 9 (2022) 18–20.
[11] J.D. Katz, A.J. Bouley, R.M. Jungquist, et al., Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab, Mult Scler Relat Szed 57 (2022), 103382.
[12] J.J. Sabatino, K. Mittl, W.M. Bowles, et al., Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T-cell immunity and function, JCI Insight 7 (2022), e156978.
[13] H.M. Bajwa, F. Novak, A.C. Nilsson, et al., Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients, Mult Scler Relat Szed 60 (2022), 103729.
[14] N. Madelon, K. Lauper, G. Breiville, et al., Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study, Clin Infect Dis (2021) ciaa954.
[15] N. Capasso, A. Nozzollillo, G. Scalia, et al., Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis, Mult Scler Relat Szed 49 (2021), 102802.
[16] P. Stefanelli, F. Trentini, D. Petroni, et al., Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021–January 2022, medRxiv (2022).
[17] Y. Cao, J. Wang, F. Jian, et al., Omicron escape the majority of existing SARS-CoV-2 neutralizing antibodies, Nature 602 (2022) 657–663.
[18] T. Brud, J. Hadjadji, P. Maes, et al., Serum neutralization of SARS-CoV-2 omicron sublinesages BA.1 and BA.2 in patients receiving monoclonal antibodies, Nat Med (2022).
[19] A.-L. Mader, L. Tydykov, V. Glück, et al., Omicron’s binding to sotrovimab, casirivimab, imdevimab, and sera from previously infected or vaccinated individuals, Science 375 (2022), 1046796.
[20] F. Touret, C. Baronti, H.S. Bouzidi, et al., In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 omicron B.1.1.529 isolate, Sci Rep 12 (2022) 10–14.
[21] S. Iketani, L. Liu, Y. Guo, et al., Antibody evasion properties of SARS-CoV-2 omicron sublineages, Nature. 604 (7906) (2022) 553–556.

[22] I. Benotmane, G.G. Vargas, S. Fafi-kremer, et al., Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (EvusheldTM) prophylaxis in kidney transplant recipients, medRxiv. (2022).

[23] M.M. King, A.S.W. Winton, A.D. Adkins, Assessing the readability of mental health internet brochures for children and adolescents, J Child Fam Stud 12 (2003) 91–99.